- SID Score
- 7.8/10
- Fair value
- $298.33
- Generated
- Sep 10, 2026
- Model
- claude-haiku-4-5-20251001
Johnson & Johnson is trading at $267.08 with a market capitalization of $505.8 billion, presenting a mixed investment picture with notable valuation support but concerning analyst consensus discrepancies. The company demonstrates strong earnings momentum with consistent beats across recent quarters (2.9 EPS actual vs. 2.85 estimated in July 2026) and a fair value estimate of $298.33, suggesting 8.4% upside potential. However, the significant gap between the fair value and the average analyst price target of $207.08 raises questions about valuation methodology consistency. The SID Score of 7.8/10 indicates reasonable overall investment quality despite mixed factor performance.
The company exhibits strong profitability fundamentals evidenced by its A-grade Growth rating and B-grade Profitability score, with recent earnings consistently beating analyst expectations across four consecutive reporting periods. The P/E ratio of 20.30 is moderate for a healthcare blue-chip, suggesting the market is pricing in reasonable growth expectations without excessive premium valuation. However, the D-grade Value rating suggests the stock may not represent compelling value at current levels, and the concerning 0.02% dividend yield appears inconsistent with J&J's historical reputation as a dividend aristocrat, warranting further investigation into payout policy changes. The lack of detailed annual financial data limits deeper analysis of balance sheet strength, cash flow generation, and debt levels.
The stock is trading near-term support levels with the 50-day moving average at $262.06 and 200-day moving average at $241.98, indicating the stock has climbed 10.4% above its 200-day average and 1.9% above its 50-day average. The RSI(14) of 47.9 suggests the stock is neither overbought nor oversold, positioning it in neutral technical territory with no immediate momentum exhaustion signals. Current price levels represent a $31.25 gap below the fair value estimate of $298.33, providing technical support from the 50-day MA while allowing room for upside movement toward intrinsic value estimates.
Analyst & Insider Sentiment
The analyst consensus of "Buy" with an average price target of $207.08 presents a significant red flag, as this represents an 18% downside from current levels and contradicts the fair value estimate of $298.33 by a substantial margin of $91.25. Recent insider activity shows executive Joaquin Duato executing large share transactions (totaling approximately 246,582 shares sold on August 13, 2026), though the simultaneous buy-back of 123,291 shares on the same date suggests portfolio rebalancing rather than outright bearish positioning. The neutral news sentiment provides limited directional guidance, and the absence of recent news summary prevents assessment of company-specific catalysts or headwinds.
The primary risk is the severe discrepancy between analyst consensus targets and fair value estimates, suggesting either inflated fair value calculations or potentially outdated analyst recommendations that could disappoint investors expecting near-term price appreciation. The weak Value rating (D-grade) indicates vulnerability to market multiple compression if growth rates disappoint or interest rates rise, particularly relevant given the elevated P/E ratio for a mature healthcare company. Additional risks include the unexpectedly low dividend yield (0.02%) that contradicts J&J's dividend-paying heritage, potential pharmaceutical pipeline disappointments, patent expirations on key products, and litigation exposure common to large pharmaceutical firms.
Johnson & Johnson represents a cautiously optimistic investment for long-term, quality-focused investors willing to overlook short-term analyst consensus concerns, supported by consistent earnings beats, reasonable valuations relative to growth, and strong fundamental scores in Growth (A) and Momentum (B) categories. The 8.4% upside to fair value ($298.33) combined with the company's market leadership in pharmaceuticals, medical devices, and consumer health provides a foundation for value creation, though investors should demand clarity on the dividend yield decline and reconcile analyst target discrepancies before committing capital. A buy recommendation is appropriate primarily for those with 2-3 year investment horizons who can tolerate the analyst consensus pessimism and capitalize on potential mean reversion toward fair value estimates, while those seeking immediate momentum or high dividend income should consider alternatives or await technical confirmation of directional strength.
